JP4309473B2 - 抗アテローム性動脈硬化剤としてのアルキル―４―シリル―フェノールおよびそのエステル - Google Patents
抗アテローム性動脈硬化剤としてのアルキル―４―シリル―フェノールおよびそのエステル Download PDFInfo
- Publication number
- JP4309473B2 JP4309473B2 JP53886297A JP53886297A JP4309473B2 JP 4309473 B2 JP4309473 B2 JP 4309473B2 JP 53886297 A JP53886297 A JP 53886297A JP 53886297 A JP53886297 A JP 53886297A JP 4309473 B2 JP4309473 B2 JP 4309473B2
- Authority
- JP
- Japan
- Prior art keywords
- phenol
- butyl
- methyloxy
- methyl
- dimethylphenylsilyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000000879 anti-atherosclerotic effect Effects 0.000 title description 7
- 150000002148 esters Chemical class 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims description 145
- -1 hydroxy, methoxy, ethoxy Chemical group 0.000 claims description 96
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 83
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 63
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims description 43
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims description 43
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 37
- 230000014509 gene expression Effects 0.000 claims description 28
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 25
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims description 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
- 201000001320 Atherosclerosis Diseases 0.000 claims description 23
- 239000001257 hydrogen Substances 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 238000004519 manufacturing process Methods 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 208000037976 chronic inflammation Diseases 0.000 claims description 12
- 102000004127 Cytokines Human genes 0.000 claims description 11
- 108090000695 Cytokines Proteins 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 8
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- CZHOOTVWJKWDAK-UHFFFAOYSA-N 4-(benzhydrylsilylmethoxy)-2,6-ditert-butylphenol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(OC[SiH2]C(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 CZHOOTVWJKWDAK-UHFFFAOYSA-N 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- HXIGAGXVWIFWDN-UHFFFAOYSA-N 2-tert-butyl-4-[[dimethyl(phenyl)silyl]methoxy]phenol Chemical compound C1=C(O)C(C(C)(C)C)=CC(OC[Si](C)(C)C=2C=CC=CC=2)=C1 HXIGAGXVWIFWDN-UHFFFAOYSA-N 0.000 claims description 4
- NITGWAPUTQFYRC-UHFFFAOYSA-N 4-[[benzyl(dimethyl)silyl]methoxy]-2-tert-butylphenol Chemical compound C1=C(O)C(C(C)(C)C)=CC(OC[Si](C)(C)CC=2C=CC=CC=2)=C1 NITGWAPUTQFYRC-UHFFFAOYSA-N 0.000 claims description 4
- 230000006020 chronic inflammation Effects 0.000 claims description 4
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 4
- 238000005502 peroxidation Methods 0.000 claims description 4
- ZMJRWWKRZNFRGQ-UHFFFAOYSA-N 2,5-ditert-butyl-4-[[dimethyl(phenyl)silyl]methoxy]phenol Chemical compound C1=C(O)C(C(C)(C)C)=CC(OC[Si](C)(C)C=2C=CC=CC=2)=C1C(C)(C)C ZMJRWWKRZNFRGQ-UHFFFAOYSA-N 0.000 claims description 3
- LTERTWMSLJHISJ-UHFFFAOYSA-N 2,6-ditert-butyl-4-[[dimethyl-[3-(trifluoromethyl)phenyl]silyl]methoxy]phenol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(OC[Si](C)(C)C=2C=C(C=CC=2)C(F)(F)F)=C1 LTERTWMSLJHISJ-UHFFFAOYSA-N 0.000 claims description 3
- RIICOPAJNTVLAM-UHFFFAOYSA-N 2,6-ditert-butyl-4-[[dimethyl-[4-(trifluoromethyl)phenyl]silyl]methoxy]phenol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(OC[Si](C)(C)C=2C=CC(=CC=2)C(F)(F)F)=C1 RIICOPAJNTVLAM-UHFFFAOYSA-N 0.000 claims description 3
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 claims description 3
- 238000008214 LDL Cholesterol Methods 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- OVAGRPMJPLBNQI-UHFFFAOYSA-N butanedioic acid;2-tert-butyl-4-[[dimethyl(phenyl)silyl]methoxy]phenol Chemical compound OC(=O)CCC(O)=O.C1=C(O)C(C(C)(C)C)=CC(OC[Si](C)(C)C=2C=CC=CC=2)=C1 OVAGRPMJPLBNQI-UHFFFAOYSA-N 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- RSJJXPGMBGBHBV-UHFFFAOYSA-N 2-tert-butyl-4-[[(4-methoxyphenyl)-dimethylsilyl]methoxy]phenol Chemical compound C1=CC(OC)=CC=C1[Si](C)(C)COC1=CC=C(O)C(C(C)(C)C)=C1 RSJJXPGMBGBHBV-UHFFFAOYSA-N 0.000 claims description 2
- FSQIGEJCTBDCBK-UHFFFAOYSA-N 2-tert-butyl-4-[[dimethyl(phenyl)silyl]methylsulfanyl]phenol Chemical compound C1=C(O)C(C(C)(C)C)=CC(SC[Si](C)(C)C=2C=CC=CC=2)=C1 FSQIGEJCTBDCBK-UHFFFAOYSA-N 0.000 claims description 2
- FMJCNQNHDMSLOS-UHFFFAOYSA-N 4-(benzhydrylsilylmethoxy)-2,5-ditert-butylphenol Chemical compound C1=C(O)C(C(C)(C)C)=CC(OC[SiH2]C(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1C(C)(C)C FMJCNQNHDMSLOS-UHFFFAOYSA-N 0.000 claims description 2
- GCKFMZQFZPUPJV-UHFFFAOYSA-N 4-[[dimethyl(phenyl)silyl]methoxy]-2,3,5-trimethylphenol Chemical compound CC1=CC(O)=C(C)C(C)=C1OC[Si](C)(C)C1=CC=CC=C1 GCKFMZQFZPUPJV-UHFFFAOYSA-N 0.000 claims description 2
- KNLSSBJTFZOUOP-UHFFFAOYSA-N C1=C(O)C(C(C)(C)C)=CC(OC[SiH2]C(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 Chemical compound C1=C(O)C(C(C)(C)C)=CC(OC[SiH2]C(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 KNLSSBJTFZOUOP-UHFFFAOYSA-N 0.000 claims description 2
- CBCWILDIHQQQMU-UHFFFAOYSA-N [2,5-ditert-butyl-4-[[dimethyl(phenyl)silyl]methoxy]phenyl] acetate Chemical compound C1=C(C(C)(C)C)C(OC(=O)C)=CC(C(C)(C)C)=C1OC[Si](C)(C)C1=CC=CC=C1 CBCWILDIHQQQMU-UHFFFAOYSA-N 0.000 claims description 2
- LCRVOORFFQBAPA-UHFFFAOYSA-N [2-tert-butyl-4-[[dimethyl(phenyl)silyl]methoxy]phenyl] acetate Chemical compound C1=C(C(C)(C)C)C(OC(=O)C)=CC=C1OC[Si](C)(C)C1=CC=CC=C1 LCRVOORFFQBAPA-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 2
- 230000005747 tumor angiogenesis Effects 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 5
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 claims 2
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 claims 1
- 125000004149 thio group Chemical group *S* 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 119
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 72
- 239000000203 mixture Substances 0.000 description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 60
- 239000003921 oil Substances 0.000 description 52
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- 210000002966 serum Anatomy 0.000 description 49
- 239000000243 solution Substances 0.000 description 46
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 238000000034 method Methods 0.000 description 27
- 239000010410 layer Substances 0.000 description 25
- 210000004185 liver Anatomy 0.000 description 25
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 24
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
- 239000011541 reaction mixture Substances 0.000 description 22
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 21
- 239000007787 solid Substances 0.000 description 21
- IPBVNPXQWQGGJP-UHFFFAOYSA-N phenyl acetate Chemical compound CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 20
- 238000010992 reflux Methods 0.000 description 18
- 241000283973 Oryctolagus cuniculus Species 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 16
- 239000000524 Thiobarbituric Acid Reactive Substance Substances 0.000 description 16
- 235000012000 cholesterol Nutrition 0.000 description 16
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- 238000002835 absorbance Methods 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 239000007788 liquid Substances 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 208000035150 Hypercholesterolemia Diseases 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 14
- 150000002632 lipids Chemical class 0.000 description 14
- 229910052757 nitrogen Inorganic materials 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 108010007622 LDL Lipoproteins Proteins 0.000 description 13
- 102000007330 LDL Lipoproteins Human genes 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 13
- 239000011777 magnesium Substances 0.000 description 13
- 229910052749 magnesium Inorganic materials 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 12
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 12
- 229940118019 malondialdehyde Drugs 0.000 description 12
- 239000002207 metabolite Substances 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 238000009835 boiling Methods 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 230000008018 melting Effects 0.000 description 11
- 238000002844 melting Methods 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- 235000011181 potassium carbonates Nutrition 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 238000007254 oxidation reaction Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 230000003647 oxidation Effects 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 239000003963 antioxidant agent Substances 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 208000029078 coronary artery disease Diseases 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 235000021067 refined food Nutrition 0.000 description 8
- 239000003643 water by type Substances 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 7
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- ITKVLPYNJQOCPW-UHFFFAOYSA-N chloro-(chloromethyl)-dimethylsilane Chemical compound C[Si](C)(Cl)CCl ITKVLPYNJQOCPW-UHFFFAOYSA-N 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 235000009518 sodium iodide Nutrition 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 6
- 102000004895 Lipoproteins Human genes 0.000 description 6
- 108090001030 Lipoproteins Proteins 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 6
- 239000012346 acetyl chloride Substances 0.000 description 6
- 150000001299 aldehydes Chemical class 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- LLVCJWMUDNMTMS-UHFFFAOYSA-N butanedioic acid;phenol Chemical compound OC1=CC=CC=C1.OC(=O)CCC(O)=O LLVCJWMUDNMTMS-UHFFFAOYSA-N 0.000 description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 6
- 229910000024 caesium carbonate Inorganic materials 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 150000001993 dienes Chemical class 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 150000003626 triacylglycerols Chemical class 0.000 description 6
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 5
- 239000007818 Grignard reagent Substances 0.000 description 5
- 108010010234 HDL Lipoproteins Proteins 0.000 description 5
- 102000015779 HDL Lipoproteins Human genes 0.000 description 5
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 210000000709 aorta Anatomy 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- RJCTVFQQNCNBHG-UHFFFAOYSA-N chloromethyl-dimethyl-phenylsilane Chemical compound ClC[Si](C)(C)C1=CC=CC=C1 RJCTVFQQNCNBHG-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 150000004795 grignard reagents Chemical class 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical class II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XFKCVVFQGHCLIP-UHFFFAOYSA-N 2-ethylbutanedioyl dichloride Chemical compound CCC(C(Cl)=O)CC(Cl)=O XFKCVVFQGHCLIP-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- 108010057466 NF-kappa B Proteins 0.000 description 4
- 102000003945 NF-kappa B Human genes 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 239000000010 aprotic solvent Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- SSQOSTRUDOUBJZ-UHFFFAOYSA-N chloromethyl-methyl-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](CCl)(C)C1=CC=CC=C1 SSQOSTRUDOUBJZ-UHFFFAOYSA-N 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 210000005119 human aortic smooth muscle cell Anatomy 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 229940028885 interleukin-4 Drugs 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000011587 new zealand white rabbit Methods 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- XHTYQFMRBQUCPX-UHFFFAOYSA-N 1,1,3,3-tetramethoxypropane Chemical compound COC(OC)CC(OC)OC XHTYQFMRBQUCPX-UHFFFAOYSA-N 0.000 description 3
- DDTHMESPCBONDT-UHFFFAOYSA-N 4-(4-oxocyclohexa-2,5-dien-1-ylidene)cyclohexa-2,5-dien-1-one Chemical compound C1=CC(=O)C=CC1=C1C=CC(=O)C=C1 DDTHMESPCBONDT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229930185605 Bisphenol Natural products 0.000 description 3
- CZEYGPCTVRWMHG-UHFFFAOYSA-N C[SiH](C)CI Chemical compound C[SiH](C)CI CZEYGPCTVRWMHG-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 238000003747 Grignard reaction Methods 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004809 Teflon Substances 0.000 description 3
- 229920006362 Teflon® Polymers 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 3
- 239000002981 blocking agent Substances 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- UVJAFXWGPBSOGS-UHFFFAOYSA-N iodomethyl-methyl-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](CI)(C)C1=CC=CC=C1 UVJAFXWGPBSOGS-UHFFFAOYSA-N 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- JFNARRJEBQBMJF-UHFFFAOYSA-N (4-hydroxy-2,3,6-trimethylphenyl) acetate Chemical compound CC(=O)OC1=C(C)C=C(O)C(C)=C1C JFNARRJEBQBMJF-UHFFFAOYSA-N 0.000 description 2
- CUJPFPXNDSIBPG-UHFFFAOYSA-N 1,3-propanediyl Chemical group [CH2]C[CH2] CUJPFPXNDSIBPG-UHFFFAOYSA-N 0.000 description 2
- AUFZRCJENRSRLY-UHFFFAOYSA-N 2,3,5-trimethylhydroquinone Chemical compound CC1=CC(O)=C(C)C(C)=C1O AUFZRCJENRSRLY-UHFFFAOYSA-N 0.000 description 2
- FHTHVIWOFOPDJZ-UHFFFAOYSA-N 2,6-ditert-butyl-4-[[dimethyl(phenyl)silyl]methoxy]phenol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(OC[Si](C)(C)C=2C=CC=CC=2)=C1 FHTHVIWOFOPDJZ-UHFFFAOYSA-N 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
- IFCULCNHRHLLRR-UHFFFAOYSA-N 2-tert-butyl-4-sulfanylphenol Chemical compound CC(C)(C)C1=CC(S)=CC=C1O IFCULCNHRHLLRR-UHFFFAOYSA-N 0.000 description 2
- SEUKIQONQZEPAZ-UHFFFAOYSA-N 4-(1-hydroxy-2-trimethylsilylethyl)-2,3,6-trimethylphenol Chemical compound CC1=CC(C(O)C[Si](C)(C)C)=C(C)C(C)=C1O SEUKIQONQZEPAZ-UHFFFAOYSA-N 0.000 description 2
- VOLAKJOSLKTFSQ-UHFFFAOYSA-N 4-[[dimethyl(phenyl)silyl]methoxy]-2,3,6-trimethylphenol Chemical compound CC1=C(O)C(C)=CC(OC[Si](C)(C)C=2C=CC=CC=2)=C1C VOLAKJOSLKTFSQ-UHFFFAOYSA-N 0.000 description 2
- XYZWMVYYUIMRIZ-UHFFFAOYSA-N 4-bromo-n,n-dimethylaniline Chemical compound CN(C)C1=CC=C(Br)C=C1 XYZWMVYYUIMRIZ-UHFFFAOYSA-N 0.000 description 2
- QJPJQTDYNZXKQF-UHFFFAOYSA-N 4-bromoanisole Chemical compound COC1=CC=C(Br)C=C1 QJPJQTDYNZXKQF-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010014476 Elevated cholesterol Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 206010048215 Xanthomatosis Diseases 0.000 description 2
- JARMUKWSAYQPKJ-UHFFFAOYSA-N [4-(bromomethyl)-2,6-dimethylphenyl] acetate Chemical compound CC(=O)OC1=C(C)C=C(CBr)C=C1C JARMUKWSAYQPKJ-UHFFFAOYSA-N 0.000 description 2
- VLVANMCLTQOYLN-UHFFFAOYSA-N [4-[[dimethyl(phenyl)silyl]methoxy]-2,3,6-trimethylphenyl] acetate Chemical compound CC1=C(C)C(OC(=O)C)=C(C)C=C1OC[Si](C)(C)C1=CC=CC=C1 VLVANMCLTQOYLN-UHFFFAOYSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- MEMDIECPWPQFCX-UHFFFAOYSA-N benzyl-(chloromethyl)-dimethylsilane Chemical compound ClC[Si](C)(C)CC1=CC=CC=C1 MEMDIECPWPQFCX-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- HTUAUFIWJUMFOE-UHFFFAOYSA-N butanedioic acid;2,6-ditert-butyl-4-(trimethylsilylmethylsulfanyl)phenol Chemical compound OC(=O)CCC(O)=O.CC(C)(C)C1=CC(SC[Si](C)(C)C)=CC(C(C)(C)C)=C1O HTUAUFIWJUMFOE-UHFFFAOYSA-N 0.000 description 2
- LUDQZZOBGAUKQC-UHFFFAOYSA-N butanedioic acid;2,6-ditert-butyl-4-[[dimethyl(phenyl)silyl]methoxy]phenol Chemical compound OC(=O)CCC(O)=O.CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(OC[Si](C)(C)C=2C=CC=CC=2)=C1 LUDQZZOBGAUKQC-UHFFFAOYSA-N 0.000 description 2
- SFDJWDKLTUIONI-UHFFFAOYSA-N butanedioic acid;2,6-ditert-butyl-4-[[dimethyl-[3-(trifluoromethyl)phenyl]silyl]methoxy]phenol Chemical compound OC(=O)CCC(O)=O.CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(OC[Si](C)(C)C=2C=C(C=CC=2)C(F)(F)F)=C1 SFDJWDKLTUIONI-UHFFFAOYSA-N 0.000 description 2
- OVOYFISGJMGLCX-UHFFFAOYSA-N butanoic acid;phenol Chemical compound CCCC(O)=O.OC1=CC=CC=C1 OVOYFISGJMGLCX-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
- OOCUOKHIVGWCTJ-UHFFFAOYSA-N chloromethyl(trimethyl)silane Chemical compound C[Si](C)(C)CCl OOCUOKHIVGWCTJ-UHFFFAOYSA-N 0.000 description 2
- VBRBYUHYJFEHTM-UHFFFAOYSA-N chloromethyl-bis(4-methoxyphenyl)-methylsilane Chemical compound C1=CC(OC)=CC=C1[Si](C)(CCl)C1=CC=C(OC)C=C1 VBRBYUHYJFEHTM-UHFFFAOYSA-N 0.000 description 2
- 238000001804 debridement Methods 0.000 description 2
- JAYBZWYBCUJLNQ-UHFFFAOYSA-N dichloro-(chloromethyl)-methylsilane Chemical compound C[Si](Cl)(Cl)CCl JAYBZWYBCUJLNQ-UHFFFAOYSA-N 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000000497 foam cell Anatomy 0.000 description 2
- 239000003517 fume Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 2
- ZHCJAYHVVSKXPM-UHFFFAOYSA-N iodomethyl-bis(4-methoxyphenyl)-methylsilane Chemical compound C1=CC(OC)=CC=C1[Si](C)(CI)C1=CC=C(OC)C=C1 ZHCJAYHVVSKXPM-UHFFFAOYSA-N 0.000 description 2
- CKNFAJPPLKSFKU-UHFFFAOYSA-N iodomethyl-dimethyl-[3-(trifluoromethyl)phenyl]silane Chemical compound IC[Si](C)(C)C1=CC=CC(C(F)(F)F)=C1 CKNFAJPPLKSFKU-UHFFFAOYSA-N 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000010525 oxidative degradation reaction Methods 0.000 description 2
- RWFHJEVTRVSDNX-UHFFFAOYSA-N phenol;propanoic acid Chemical compound CCC(O)=O.OC1=CC=CC=C1 RWFHJEVTRVSDNX-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 150000004756 silanes Chemical class 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- OMIVCRYZSXDGAB-UHFFFAOYSA-N 1,4-butanediyl Chemical group [CH2]CC[CH2] OMIVCRYZSXDGAB-UHFFFAOYSA-N 0.000 description 1
- RWXUNIMBRXGNEP-UHFFFAOYSA-N 1-bromo-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1Br RWXUNIMBRXGNEP-UHFFFAOYSA-N 0.000 description 1
- NNMBNYHMJRJUBC-UHFFFAOYSA-N 1-bromo-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(Br)=C1 NNMBNYHMJRJUBC-UHFFFAOYSA-N 0.000 description 1
- XLQSXGGDTHANLN-UHFFFAOYSA-N 1-bromo-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(Br)C=C1 XLQSXGGDTHANLN-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- JBUVVICBTIYGBC-UHFFFAOYSA-N 2,3,6-trimethyl-4-(2-trimethylsilylethyl)phenol Chemical compound CC1=CC(CC[Si](C)(C)C)=C(C)C(C)=C1O JBUVVICBTIYGBC-UHFFFAOYSA-N 0.000 description 1
- JZODKRWQWUWGCD-UHFFFAOYSA-N 2,5-di-tert-butylbenzene-1,4-diol Chemical compound CC(C)(C)C1=CC(O)=C(C(C)(C)C)C=C1O JZODKRWQWUWGCD-UHFFFAOYSA-N 0.000 description 1
- OGICGGHLDGDLJH-UHFFFAOYSA-N 2,5-ditert-butyl-4-[2-[ditert-butyl(phenyl)silyl]ethyl]phenol;2,5-ditert-butyl-4-[2-[dimethyl(phenyl)silyl]ethyl]phenol;2,5-ditert-butyl-4-(2-tritert-butylsilylethyl)phenol Chemical compound C1=C(O)C(C(C)(C)C)=CC(CC[Si](C)(C)C=2C=CC=CC=2)=C1C(C)(C)C.CC(C)(C)C1=CC(CC[Si](C(C)(C)C)(C(C)(C)C)C(C)(C)C)=C(C(C)(C)C)C=C1O.C1=C(O)C(C(C)(C)C)=CC(CC[Si](C=2C=CC=CC=2)(C(C)(C)C)C(C)(C)C)=C1C(C)(C)C OGICGGHLDGDLJH-UHFFFAOYSA-N 0.000 description 1
- NQHFAZBCHXYAQT-UHFFFAOYSA-N 2,6-ditert-butyl-4-(trimethylsilylmethylsulfanyl)phenol Chemical compound CC(C)(C)C1=CC(SC[Si](C)(C)C)=CC(C(C)(C)C)=C1O NQHFAZBCHXYAQT-UHFFFAOYSA-N 0.000 description 1
- NMGQDUYLWFFFEI-UHFFFAOYSA-N 2,6-ditert-butyl-4-[[dimethyl(phenyl)silyl]methylsulfanyl]phenol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(SC[Si](C)(C)C=2C=CC=CC=2)=C1 NMGQDUYLWFFFEI-UHFFFAOYSA-N 0.000 description 1
- AGJGQKFZGIQFPZ-UHFFFAOYSA-N 2,6-ditert-butyl-4-[[dimethyl-[3-(trifluoromethyl)phenyl]silyl]methoxy]phenol 4-[[dimethyl-[4-(trifluoromethyl)phenyl]silyl]methoxy]-2,3,6-trimethylphenol Chemical compound C(C)(C)(C)C1=C(C(=CC(=C1)OC[Si](C1=CC(=CC=C1)C(F)(F)F)(C)C)C(C)(C)C)O.CC1=C(C(=CC(=C1C)OC[Si](C1=CC=C(C=C1)C(F)(F)F)(C)C)C)O AGJGQKFZGIQFPZ-UHFFFAOYSA-N 0.000 description 1
- NFVMNXZFSKGLDR-UHFFFAOYSA-N 2,6-ditert-butyl-4-sulfanylphenol Chemical compound CC(C)(C)C1=CC(S)=CC(C(C)(C)C)=C1O NFVMNXZFSKGLDR-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- PKRSYEPBQPFNRB-UHFFFAOYSA-N 2-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- CNHYMBAKOONSJD-UHFFFAOYSA-N 4-(2-benzhydrylsilylethyl)-2,6-ditert-butylphenol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(CC[SiH2]C(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 CNHYMBAKOONSJD-UHFFFAOYSA-N 0.000 description 1
- PVQUEBMXSXCSSZ-UHFFFAOYSA-N 4-(bromomethyl)-2,6-diethylphenol Chemical compound CCC1=CC(CBr)=CC(CC)=C1O PVQUEBMXSXCSSZ-UHFFFAOYSA-N 0.000 description 1
- YEOQCOZNFXPHHY-UHFFFAOYSA-N 4-(bromomethyl)-2,6-ditert-butylphenol Chemical compound CC(C)(C)C1=CC(CBr)=CC(C(C)(C)C)=C1O YEOQCOZNFXPHHY-UHFFFAOYSA-N 0.000 description 1
- ZSWGASACQXSPCY-UHFFFAOYSA-N 4-[2-[dimethyl(phenyl)silyl]ethyl]-2,3,6-trimethylphenol Chemical compound CC1=C(O)C(C)=CC(CC[Si](C)(C)C=2C=CC=CC=2)=C1C ZSWGASACQXSPCY-UHFFFAOYSA-N 0.000 description 1
- QUNPWNNROVFQEB-UHFFFAOYSA-N 4-[2-[dimethyl(phenyl)silyl]ethyl]-2,5-dipropylphenol 2,5-di(propan-2-yl)-4-(2-trimethylsilylethyl)phenol 2,5-dipropyl-4-(2-trimethylsilylethyl)phenol Chemical compound C(C)(C)C1=C(C=C(C(=C1)CC[Si](C)(C)C)C(C)C)O.C(CC)C1=C(C=C(C(=C1)CC[Si](C1=CC=CC=C1)(C)C)CCC)O.C(CC)C1=C(C=C(C(=C1)CC[Si](C)(C)C)CCC)O QUNPWNNROVFQEB-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- LRRULYRVDZNOOF-UHFFFAOYSA-N 4-hydroxy-2,3,5-trimethylbenzaldehyde Chemical compound CC1=CC(C=O)=C(C)C(C)=C1O LRRULYRVDZNOOF-UHFFFAOYSA-N 0.000 description 1
- ZYUVGYBAPZYKSA-UHFFFAOYSA-N 5-(3-hydroxybutan-2-yl)-4-methylbenzene-1,3-diol Chemical compound CC(O)C(C)C1=CC(O)=CC(O)=C1C ZYUVGYBAPZYKSA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 238000006027 Birch reduction reaction Methods 0.000 description 1
- RYXVARCWTHNSAR-UHFFFAOYSA-N C(C)(C)(C)C1=C(C=C(C(=C1)CC[Si](C)(C)C)C(C)(C)C)O.C(CCC)C1=C(C=C(C(=C1)CC[Si](C1=CC=CC=C1)(C)C)CCCC)O.C(CCC)C1=C(C=C(C(=C1)CC[Si](C)(C)C)CCCC)O Chemical compound C(C)(C)(C)C1=C(C=C(C(=C1)CC[Si](C)(C)C)C(C)(C)C)O.C(CCC)C1=C(C=C(C(=C1)CC[Si](C1=CC=CC=C1)(C)C)CCCC)O.C(CCC)C1=C(C=C(C(=C1)CC[Si](C)(C)C)CCCC)O RYXVARCWTHNSAR-UHFFFAOYSA-N 0.000 description 1
- BOSOOQCXIAXPJK-UHFFFAOYSA-N C(C)(C)(C)C1=C(C=CC(=C1)CC[Si](C)(C)C)O.CC1=C(C=C(C(=C1)CC[Si](C1=CC=CC=C1)(C)C)C)O.CC1=C(C=C(C(=C1)CC[Si](C)(C)C)C)O Chemical compound C(C)(C)(C)C1=C(C=CC(=C1)CC[Si](C)(C)C)O.CC1=C(C=C(C(=C1)CC[Si](C1=CC=CC=C1)(C)C)C)O.CC1=C(C=C(C(=C1)CC[Si](C)(C)C)C)O BOSOOQCXIAXPJK-UHFFFAOYSA-N 0.000 description 1
- UENYVYTUFLRLRU-UHFFFAOYSA-N C(C)(C)(C)C1=C(C=CC(=C1)CC[Si](C1=CC=CC=C1)(C)C)O.C(C)(C)(C)C1=C(C=CC(=C1)CC[Si](C)(C)C)O.C(C)(C)(C)C1=C(C=CC(=C1)CC[Si](C1=CC=CC=C1)(C)C)O Chemical compound C(C)(C)(C)C1=C(C=CC(=C1)CC[Si](C1=CC=CC=C1)(C)C)O.C(C)(C)(C)C1=C(C=CC(=C1)CC[Si](C)(C)C)O.C(C)(C)(C)C1=C(C=CC(=C1)CC[Si](C1=CC=CC=C1)(C)C)O UENYVYTUFLRLRU-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100024649 Cell adhesion molecule 1 Human genes 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101100001675 Emericella variicolor andJ gene Proteins 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102100022339 Integrin alpha-L Human genes 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- IGVPBCZDHMIOJH-UHFFFAOYSA-N Phenyl butyrate Chemical compound CCCC(=O)OC1=CC=CC=C1 IGVPBCZDHMIOJH-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- VSWDORGPIHIGNW-UHFFFAOYSA-N Pyrrolidine dithiocarbamic acid Chemical compound SC(=S)N1CCCC1 VSWDORGPIHIGNW-UHFFFAOYSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- VVEGUOLKIUABHY-UHFFFAOYSA-N [2,6-ditert-butyl-4-[[dimethyl(phenyl)silyl]methoxy]phenyl] acetate Chemical compound C1=C(C(C)(C)C)C(OC(=O)C)=C(C(C)(C)C)C=C1OC[Si](C)(C)C1=CC=CC=C1 VVEGUOLKIUABHY-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000008369 airway response Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000006427 angiogenic response Effects 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- ACAUYCZBWABOLI-UHFFFAOYSA-N bromomethyl(trimethyl)silane Chemical compound C[Si](C)(C)CBr ACAUYCZBWABOLI-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- HQVIRBJFKWKPPK-UHFFFAOYSA-N butanedioic acid;2,6-ditert-butyl-4-[[dimethyl(phenyl)silyl]methylsulfanyl]phenol Chemical compound OC(=O)CCC(O)=O.CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(SC[Si](C)(C)C=2C=CC=CC=2)=C1 HQVIRBJFKWKPPK-UHFFFAOYSA-N 0.000 description 1
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- OJZNZOXALZKPEA-UHFFFAOYSA-N chloro-methyl-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C)C1=CC=CC=C1 OJZNZOXALZKPEA-UHFFFAOYSA-N 0.000 description 1
- HZWZGJQFUHYQOD-UHFFFAOYSA-N chloromethyl(dichloromethyl)silane Chemical compound ClC[SiH2]C(Cl)Cl HZWZGJQFUHYQOD-UHFFFAOYSA-N 0.000 description 1
- BHLKIZCNPYDMOY-UHFFFAOYSA-N chloromethyl(dimethyl)silane Chemical compound C[SiH](C)CCl BHLKIZCNPYDMOY-UHFFFAOYSA-N 0.000 description 1
- ZDDHJUVYEZIQOF-UHFFFAOYSA-N chloromethyl-(2,3-dimethylphenyl)-(trifluoromethyl)silane Chemical compound CC=1C(=C(C=CC=1)[SiH](C(F)(F)F)CCl)C ZDDHJUVYEZIQOF-UHFFFAOYSA-N 0.000 description 1
- GWZIEVDUMGBXHM-UHFFFAOYSA-N chloromethyl-(2-methoxyphenyl)-dimethylsilane Chemical compound COC1=CC=CC=C1[Si](C)(C)CCl GWZIEVDUMGBXHM-UHFFFAOYSA-N 0.000 description 1
- XEGINBFTQWDRPY-UHFFFAOYSA-N chloromethyl-dimethyl-[3-(trifluoromethyl)phenyl]silane Chemical compound ClC[Si](C)(C)C1=CC=CC(C(F)(F)F)=C1 XEGINBFTQWDRPY-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- NHADDZMCASKINP-HTRCEHHLSA-N decarboxydihydrocitrinin Natural products C1=C(O)C(C)=C2[C@H](C)[C@@H](C)OCC2=C1O NHADDZMCASKINP-HTRCEHHLSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- PIZLBWGMERQCOC-UHFFFAOYSA-N dibenzyl carbonate Chemical compound C=1C=CC=CC=1COC(=O)OCC1=CC=CC=C1 PIZLBWGMERQCOC-UHFFFAOYSA-N 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- LVQOKPYWSBORCX-UHFFFAOYSA-L disodium phosphoric acid sulfate Chemical compound S(=O)(=O)([O-])[O-].[Na+].P(O)(O)(O)=O.[Na+] LVQOKPYWSBORCX-UHFFFAOYSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000026721 endothelial cell chemotaxis Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- LNQUWGZAZIOHMM-UHFFFAOYSA-N ethoxy-hydroxy-methoxy-lambda3-chlorane Chemical compound CCOCl(O)OC LNQUWGZAZIOHMM-UHFFFAOYSA-N 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- VZNYXGQMDSRJAL-UHFFFAOYSA-N iodomethyl(trimethyl)silane Chemical compound C[Si](C)(C)CI VZNYXGQMDSRJAL-UHFFFAOYSA-N 0.000 description 1
- UBEKYOFKZKLRHY-UHFFFAOYSA-N iodomethyl-(4-methoxyphenyl)-dimethylsilane Chemical compound COC1=CC=C([Si](C)(C)CI)C=C1 UBEKYOFKZKLRHY-UHFFFAOYSA-N 0.000 description 1
- CTJNLNJXHJPLPZ-UHFFFAOYSA-N iodomethyl-dimethyl-[4-(trifluoromethyl)phenyl]silane Chemical compound IC[Si](C)(C)C1=CC=C(C(F)(F)F)C=C1 CTJNLNJXHJPLPZ-UHFFFAOYSA-N 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- FHFHPENPORXWHG-UHFFFAOYSA-N magnesium;phenol Chemical compound [Mg].OC1=CC=CC=C1 FHFHPENPORXWHG-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003209 petroleum derivative Substances 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical compound Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 1
- PARWUHTVGZSQPD-UHFFFAOYSA-N phenylsilane Chemical compound [SiH3]C1=CC=CC=C1 PARWUHTVGZSQPD-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000008259 solid foam Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 125000005314 unsaturated fatty acid group Chemical group 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 230000004865 vascular response Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/637,968 | 1996-04-30 | ||
| US08/637,968 US5608095A (en) | 1996-04-30 | 1996-04-30 | Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents |
| PCT/US1997/003335 WO1997041129A1 (en) | 1996-04-30 | 1997-03-03 | Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001509782A JP2001509782A (ja) | 2001-07-24 |
| JP2001509782A5 JP2001509782A5 (enExample) | 2004-12-02 |
| JP4309473B2 true JP4309473B2 (ja) | 2009-08-05 |
Family
ID=24558107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53886297A Expired - Fee Related JP4309473B2 (ja) | 1996-04-30 | 1997-03-03 | 抗アテローム性動脈硬化剤としてのアルキル―４―シリル―フェノールおよびそのエステル |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5608095A (enExample) |
| EP (1) | EP0900225B1 (enExample) |
| JP (1) | JP4309473B2 (enExample) |
| KR (1) | KR100503181B1 (enExample) |
| CN (1) | CN1216993A (enExample) |
| AR (1) | AR006890A1 (enExample) |
| AT (1) | ATE212639T1 (enExample) |
| AU (1) | AU711322B2 (enExample) |
| BR (1) | BR9709190A (enExample) |
| CA (1) | CA2251991C (enExample) |
| DE (1) | DE69710191T2 (enExample) |
| DK (1) | DK0900225T3 (enExample) |
| ES (1) | ES2167716T3 (enExample) |
| IL (1) | IL126758A0 (enExample) |
| NO (1) | NO985039L (enExample) |
| PT (1) | PT900225E (enExample) |
| TW (1) | TW474940B (enExample) |
| WO (1) | WO1997041129A1 (enExample) |
| ZA (1) | ZA973503B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795876A (en) * | 1996-04-30 | 1998-08-18 | Hoechst Marion Rousssel, Inc. | Method of inhibiting vascular cell adhesion molecule-1 and treating chronic inflammatory diseases with 2, 6-di-alkyl-4-silyl-phenols |
| KR20000065102A (ko) * | 1996-04-30 | 2000-11-06 | 게리 디. 스트리트, 스티븐 엘. 네스비트 | 2,6-디-알킬-4-실릴-페놀을사용한혈관세포흡착분자-1의억제방법및만성염증성질병의치료방법 |
| US6670398B2 (en) * | 1997-05-14 | 2003-12-30 | Atherogenics, Inc. | Compounds and methods for treating transplant rejection |
| EA200800375A1 (ru) * | 1997-05-14 | 2008-06-30 | Атеродженикс, Инк. | Соединения и способы ингибирования экспрессии vcam-1 |
| US6121463A (en) * | 1997-06-24 | 2000-09-19 | Hoechst Marion Roussel, Inc. | Alkyl-4-silylheterocyclic phenols and thiophenols useful as antioxidant agents |
| US6133467A (en) * | 1997-06-25 | 2000-10-17 | Hoechst Marion Roussel, Inc. | 2,6-di-t-butyl-4-[(dimethyl-4-methoxyphenylsilyl)-methyl-oxy]phenol and 2,6-di-t-butyl-4-[(dimethyl-2-methoxy-phenylsilyl)methyloxy]phenol |
| JP2002506443A (ja) * | 1997-06-25 | 2002-02-26 | アベンティス・ファーマスーティカルズ・インコーポレイテッド | ２，６−ジ−ｔ−ブチル−４−［（ジメチル−４−メトキシフェニルシリル）メチルオキシ］フェノール及び２，６−ジ−ｔ−ブチル−４−［（ジメチル−２−メトキシフェニルシリル）メチルオキシ］フェノール |
| KR20010020611A (ko) * | 1997-07-01 | 2001-03-15 | 아테로제닉스, 인코포레이티드 | 항산화제에 의한 과증식질병 치료의 향상 |
| US6887712B1 (en) | 1998-11-09 | 2005-05-03 | Atherogenics, Inc. | Methods and compositions to lower plasma cholesterol levels |
| CA2350316A1 (en) * | 1998-11-09 | 2000-05-18 | Atherogenics, Inc. | Methods and compositions to lower plasma cholesterol levels |
| US6020383A (en) * | 1999-01-11 | 2000-02-01 | Eastman Chemicals Company | Method for reducing blood cholesterol and/or blood triglycerides |
| WO2002040021A2 (en) | 2000-11-17 | 2002-05-23 | Idenix (Cayman) Limited | Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines |
| WO2002087556A2 (en) * | 2001-04-11 | 2002-11-07 | Atherogenics, Inc. | Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality |
| WO2003039231A2 (en) * | 2001-10-25 | 2003-05-15 | Atherogenics, Inc. | Compounds and methods for treating transplant rejection |
| IL161741A0 (en) * | 2001-11-09 | 2005-11-20 | Atherogenics Inc | Methods of reversing and preventingcardiovascular pathologies |
| CN1596240A (zh) * | 2001-12-19 | 2005-03-16 | 阿特罗吉尼克斯公司 | 查耳酮衍生物及其治疗疾病的用途 |
| AU2003253887A1 (en) * | 2002-07-12 | 2004-02-02 | Atherogenics, Inc. | Novel salt forms of poorly soluble probucol esters and ethers |
| US20040110803A1 (en) * | 2002-09-13 | 2004-06-10 | Hossein Dovlatabadi | Methods and compositions for the use of D-malic acid to decrease serum triglyceride, cholesterol and lipoprotein levels |
| WO2004056727A2 (en) * | 2002-12-19 | 2004-07-08 | Atherogenics, Inc. | Process of making chalcone derivatives |
| BRPI0406738A (pt) * | 2003-01-13 | 2005-12-20 | Atherogenics Inc | Processo de preparação de ésteres e éteres de probucol e derivados desse |
| WO2004108094A2 (en) * | 2003-06-06 | 2004-12-16 | Atherogenics, Inc. | Sulfonamide-substituted chalcone derivatives and their use to treat diseases |
| WO2005039596A1 (en) * | 2003-10-17 | 2005-05-06 | Amylin Pharmaceuticals, Inc. | Silyl phenols for promoting vascular health |
| US7294737B2 (en) | 2004-04-20 | 2007-11-13 | Atherogenics, Inc. | Process of preparing esters and ethers of probucol and derivatives thereof |
| WO2005112914A2 (en) | 2004-04-20 | 2005-12-01 | Atherogenics, Inc. | Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease |
| US20060063828A1 (en) * | 2004-06-28 | 2006-03-23 | Weingarten M D | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof |
| AU2005262390B2 (en) * | 2004-07-01 | 2011-09-22 | Atherogenics, Inc. | Compounds and methods for treating diabetic vascular diseases |
| JP2010522762A (ja) * | 2007-03-26 | 2010-07-08 | サルトリア・フアーマシユーテイカルズ・エル・エル・シー | 糖尿病の治療のための方法及びプロブコール誘導体の組成物 |
| US20080280985A1 (en) * | 2007-03-27 | 2008-11-13 | Scott Robert A D | Methods and Compositions Using Certain Phenolic Derivatives for the Treatment of Diabetes |
| JP5778755B2 (ja) * | 2010-04-15 | 2015-09-16 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ヒドロキノンの製造方法 |
| JP6447858B2 (ja) * | 2016-07-08 | 2019-01-09 | Ｙａｎｃｈｅｒｓ株式会社 | 固形癌治療剤 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3129262A (en) * | 1962-10-08 | 1964-04-14 | Consolidation Coal Co | Reduction of organic thiocyanates |
| US3862332A (en) * | 1967-05-11 | 1975-01-21 | Dow Chemical Co | Method of lowering serum cholesterol |
| US3576883A (en) * | 1969-06-30 | 1971-04-27 | Consolidation Coal Co | Alkylidenedithiobisphenols |
| US3897500A (en) * | 1971-12-10 | 1975-07-29 | Continental Oil Co | Alkylidenedithiobisphenols |
| US3786100A (en) * | 1971-12-10 | 1974-01-15 | Continental Oil Co | Keto substituted alkylidenedithiobisphenols |
| JPS61263988A (ja) * | 1985-05-16 | 1986-11-21 | Shionogi & Co Ltd | シリル置換エ−テル類および殺虫・殺ダニ剤 |
| US5356917A (en) * | 1985-08-09 | 1994-10-18 | Eli Lilly And Company | Aryl-substituted rhodanine derivatives |
| US4719237A (en) * | 1986-01-28 | 1988-01-12 | Merrell Dow Pharmaceuticals Inc. | Cardiac antiarrythmic method employing probucol |
| US4734527A (en) * | 1986-10-17 | 1988-03-29 | Merrell Dow Pharmaceuticals Inc. | Process for preparing 2,6-di-tertiarybutyl-4-mercaptophenol |
| US4772363A (en) * | 1987-01-14 | 1988-09-20 | Merrell Dow Pharmaceuticals Inc. | Process for preparing 2,6-di-tertiarybutyl-4-mercaptophenol by electrocatalysis |
| US4861443A (en) * | 1987-01-14 | 1989-08-29 | Merrell Dow Pharmaceuticals Inc. | Process for preparing 4,4'-isopropylidenedithio-bis-(2,6-di-tertiarybutylphenol) by electrocatalysis |
| US5401883A (en) * | 1987-01-20 | 1995-03-28 | Merrell Dow Pharmaceuticals Inc. | Process for preparing 2,6-di-tertiarybutyl-4-mercaptophenol and 4,4'-isopropylidenedithio-bis-(2,6-di-tertiarybutylphenol) |
| US4975467A (en) * | 1987-03-17 | 1990-12-04 | Merrell Dow Pharmaceuticals Inc. | Method of inhibiting interleukin-1 release and alleviating interleukin-1 mediated conditions |
| JPH0813824B2 (ja) * | 1988-10-27 | 1996-02-14 | 北興化学工業株式会社 | 有機ケイ素化合物 |
| US4900757A (en) * | 1988-12-08 | 1990-02-13 | Merrell Dow Pharmaceuticals Inc. | Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane |
| US5047555A (en) * | 1988-12-13 | 1991-09-10 | Tanabe Seiyaku Co., Ltd. | 4-aminophenol derivatives and processes for preparing the same |
| US5217870A (en) * | 1989-04-28 | 1993-06-08 | Biogen, Inc. | Monoclonal antibodies against CDX |
| US5272263A (en) * | 1989-04-28 | 1993-12-21 | Biogen, Inc. | DNA sequences encoding vascular cell adhesion molecules (VCAMS) |
| US5008421A (en) * | 1989-07-05 | 1991-04-16 | Aristech Chemical Corporation | Silyl derivatives of 2,6-dimethyl-4-allyl phenol |
| DE3935638A1 (de) * | 1989-10-26 | 1991-05-02 | Consortium Elektrochem Ind | Organosilylalkylaromaten |
| US5061734A (en) * | 1990-05-09 | 1991-10-29 | Merrell Dow Pharmaceuticals Inc. | Bis(alkyl-substituted-4-hydroxyphenylthio)alkane analogs as inhibitors of cataractogenesis |
| US5112870A (en) * | 1990-05-09 | 1992-05-12 | Merrell Dow Pharmaceuticals Inc. | Bis(alkyl-substituted-4-hydroxyphenylthio)alkane analogs as inhibitors of cataractogenesis |
| JP2899064B2 (ja) * | 1990-05-23 | 1999-06-02 | キヤノン株式会社 | 液晶性化合物、これを含む液晶組成物およびこれを使用した液晶素子 |
| US5304668A (en) * | 1990-07-05 | 1994-04-19 | Merrell Dow Pharmaceuticals | Bis-[4-(2,6-di-alkyl)phenolisilane derivatives as antiatherosclerotic agents |
| US5155250A (en) * | 1990-07-05 | 1992-10-13 | Merrell Dow Pharmaceuticals Inc. | 2,6-di-alkyl-4-silyl-phenols as antiatheroscerotic agents |
| NZ238807A (en) * | 1990-07-05 | 1994-03-25 | Merrell Dow Pharma | Bis[4-(2,6-dialkyl)phenol]silane derivatives and antiatherosclerotic compositions |
| US5254549A (en) * | 1991-12-19 | 1993-10-19 | Merz & Co. Gmbh & Co. | New BHT ether compounds and their use as hypolipidemic and antiatherosclerotic drugs |
| US5262439A (en) * | 1992-04-30 | 1993-11-16 | The Regents Of The University Of California | Soluble analogs of probucol |
| NZ299210A (en) * | 1992-09-02 | 2000-08-25 | Isis Pharmaceuticals Inc | Treating diseases characterised by changes in intercellular adhesion molecules using coding sequences hybridizable with those encoding proteins involved in synthesis of such molecules |
| US5380747A (en) * | 1992-10-30 | 1995-01-10 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
| USRE40811E1 (en) * | 1992-11-13 | 2009-06-30 | Board Of Regents Of The University Of Washington | Peripheralization of hematopoietic stem cells |
| AU5833494A (en) * | 1992-12-22 | 1994-07-19 | Smithkline Beecham Plc | Piperidine derivatives as calcium channel antagonists |
| SG44845A1 (en) * | 1993-01-12 | 1997-12-19 | Biogen Inc | Recombitant anti-vla4 antibody molecules |
| WO1994017828A2 (en) * | 1993-02-09 | 1994-08-18 | Biogen, Inc. | Treatment for insulin dependent diabetes |
| WO1995004749A1 (en) * | 1993-08-05 | 1995-02-16 | Isis Pharmaceuticals, Inc. | Oligomers for modulating metabolic function |
| JP3650144B2 (ja) * | 1994-06-08 | 2005-05-18 | 花王株式会社 | 細胞接着抑制剤 |
-
1996
- 1996-04-30 US US08/637,968 patent/US5608095A/en not_active Expired - Fee Related
-
1997
- 1997-03-03 IL IL12675897A patent/IL126758A0/xx unknown
- 1997-03-03 AU AU19854/97A patent/AU711322B2/en not_active Ceased
- 1997-03-03 JP JP53886297A patent/JP4309473B2/ja not_active Expired - Fee Related
- 1997-03-03 CA CA002251991A patent/CA2251991C/en not_active Expired - Fee Related
- 1997-03-03 BR BR9709190A patent/BR9709190A/pt active Search and Examination
- 1997-03-03 DE DE69710191T patent/DE69710191T2/de not_active Expired - Fee Related
- 1997-03-03 ES ES97907998T patent/ES2167716T3/es not_active Expired - Lifetime
- 1997-03-03 EP EP97907998A patent/EP0900225B1/en not_active Expired - Lifetime
- 1997-03-03 KR KR1019980708692A patent/KR100503181B1/ko not_active Expired - Fee Related
- 1997-03-03 CN CN97194267A patent/CN1216993A/zh active Pending
- 1997-03-03 AT AT97907998T patent/ATE212639T1/de not_active IP Right Cessation
- 1997-03-03 PT PT97907998T patent/PT900225E/pt unknown
- 1997-03-03 DK DK97907998T patent/DK0900225T3/da active
- 1997-03-03 WO PCT/US1997/003335 patent/WO1997041129A1/en not_active Ceased
- 1997-04-23 TW TW086105269A patent/TW474940B/zh active
- 1997-04-23 ZA ZA9703503A patent/ZA973503B/xx unknown
- 1997-04-29 AR ARP970101749A patent/AR006890A1/es unknown
-
1998
- 1998-10-29 NO NO985039A patent/NO985039L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT900225E (pt) | 2002-06-28 |
| IL126758A0 (en) | 1999-08-17 |
| KR100503181B1 (ko) | 2006-03-03 |
| DK0900225T3 (da) | 2002-05-13 |
| JP2001509782A (ja) | 2001-07-24 |
| CA2251991C (en) | 2002-05-14 |
| EP0900225A1 (en) | 1999-03-10 |
| US5608095A (en) | 1997-03-04 |
| BR9709190A (pt) | 1999-08-10 |
| DE69710191T2 (de) | 2002-07-25 |
| NO985039D0 (no) | 1998-10-29 |
| AU711322B2 (en) | 1999-10-14 |
| AU1985497A (en) | 1997-11-19 |
| KR20000065101A (ko) | 2000-11-06 |
| WO1997041129A1 (en) | 1997-11-06 |
| NO985039L (no) | 1998-12-21 |
| ES2167716T3 (es) | 2002-05-16 |
| ZA973503B (en) | 1997-10-30 |
| CN1216993A (zh) | 1999-05-19 |
| CA2251991A1 (en) | 1997-11-06 |
| DE69710191D1 (de) | 2002-03-14 |
| EP0900225B1 (en) | 2002-01-30 |
| TW474940B (en) | 2002-02-01 |
| AR006890A1 (es) | 1999-09-29 |
| ATE212639T1 (de) | 2002-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5608095A (en) | Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents | |
| JP2009132710A (ja) | 抗酸化剤として有用な置換フェノールおよびチオフェノール | |
| US6114572A (en) | Substituted phenols and thiophenols useful as antioxidant agents | |
| US6121463A (en) | Alkyl-4-silylheterocyclic phenols and thiophenols useful as antioxidant agents | |
| AU731278B2 (en) | Alkyl-4-silylheterocyclic phenols and thiophenols as antioxidant agents | |
| MXPA98009012A (en) | Rent-4-silil-phenoles and esters of the same as agents antiateroscleroti | |
| HK1021970B (en) | Substituted phenols and thiophenols useful as antioxidant agents | |
| MXPA99011872A (en) | Alkyl-4-silylheterocyclic phenols and thiophenols as antioxidant agents | |
| HUP9903447A2 (hu) | Arteroszklerózis-ellenes hatású alkil-4-szilil-fenolok és észtereik | |
| MXPA99004653A (en) | Substituted phenols and thiophenols useful as antioxidant agents | |
| HK1027815B (en) | Alkyl-4-silylheterocyclic phenols and thiophenols as antioxidant agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040302 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040302 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070807 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20070731 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20070725 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20070725 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071106 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071217 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080207 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080826 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081222 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20090402 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090414 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090508 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120515 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120515 Year of fee payment: 3 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120515 Year of fee payment: 3 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120515 Year of fee payment: 3 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| LAPS | Cancellation because of no payment of annual fees |